Prothena Corporation plc (PRTA)
PRTA Stock Price Chart
Explore Prothena Corporation plc interactive price chart. Choose custom timeframes to analyze PRTA price movements and trends.
PRTA Company Profile
Discover essential business fundamentals and corporate details for Prothena Corporation plc (PRTA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Dec 2012
Employees
163.00
Website
https://www.prothena.comCEO
Gene G. Kinney
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA Financial Timeline
Browse a chronological timeline of Prothena Corporation plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.68.
Earnings released on 4 Aug 2025
EPS came in at -$1.86 falling short of the estimated -$1.11 by -67.57%, while revenue for the quarter reached $4.42M , missing expectations by -33.42%.
Earnings released on 8 May 2025
EPS came in at -$1.12 falling short of the estimated -$0.92 by -21.74%, while revenue for the quarter reached $2.83M , missing expectations by -81.56%.
Earnings released on 20 Feb 2025
EPS came in at -$1.08 falling short of the estimated -$1.02 by -5.88%, while revenue for the quarter reached $2.12M , missing expectations by -71.82%.
Earnings released on 12 Nov 2024
EPS came in at -$1.10 surpassing the estimated -$1.18 by +6.78%, while revenue for the quarter reached $970.00K , missing expectations by -21.14%.
Earnings released on 8 Aug 2024
EPS came in at $1.22 surpassing the estimated -$1.05 by +216.19%, while revenue for the quarter reached $132.01M , beating expectations by +1.13K%.
Earnings released on 8 May 2024
EPS came in at -$1.34 falling short of the estimated -$1.21 by -10.74%, while revenue for the quarter reached $50.00K , missing expectations by -97.28%.
Earnings released on 15 Feb 2024
EPS came in at -$1.26 falling short of the estimated -$1.23 by -2.44%, while revenue for the quarter reached $316.00K , missing expectations by -85.30%.
Earnings released on 2 Nov 2023
EPS came in at $0.38 surpassing the estimated -$0.32 by +218.75%, while revenue for the quarter reached $84.87M , beating expectations by +103.56%.
Earnings released on 3 Aug 2023
EPS came in at -$1.03 falling short of the estimated -$0.92 by -11.96%, while revenue for the quarter reached $4.02M , missing expectations by -11.08%.
Earnings released on 4 May 2023
EPS came in at -$0.89 falling short of the estimated -$0.83 by -7.23%, while revenue for the quarter reached $2.17M , missing expectations by -52.01%.
Earnings released on 23 Feb 2023
EPS came in at $0.12 surpassing the estimated -$0.47 by +125.53%, while revenue for the quarter reached $49.92M , beating expectations by +577.38%.
Earnings released on 3 Nov 2022
EPS came in at -$0.97 falling short of the estimated -$0.31 by -212.90%, while revenue for the quarter reached $1.52M , missing expectations by -93.98%.
Earnings released on 8 Aug 2022
EPS came in at -$0.88 falling short of the estimated -$0.51 by -72.55%, while revenue for the quarter reached $1.31M , missing expectations by -92.36%.
Earnings released on 5 May 2022
EPS came in at -$0.78 surpassing the estimated -$0.85 by +8.24%, while revenue for the quarter reached $1.15M , missing expectations by -85.74%.
Earnings released on 17 Feb 2022
EPS came in at -$0.71 surpassing the estimated -$0.74 by +4.05%, while revenue for the quarter reached $1.17M , missing expectations by -83.53%.
Earnings released on 4 Nov 2021
EPS came in at $2.13 falling short of the estimated $2.28 by -6.58%, while revenue for the quarter reached $139.17M , missing expectations by -0.63%.
Earnings released on 5 Aug 2021
EPS came in at $0.58 falling short of the estimated $1.00 by -42.00%, while revenue for the quarter reached $60.07M , missing expectations by -14.43%.
Earnings released on 11 May 2021
EPS came in at -$0.91 falling short of the estimated -$0.80 by -13.75%, while revenue for the quarter reached $160.00K , beating expectations by +28.34%.
Earnings released on 11 Feb 2021
EPS came in at -$0.77 surpassing the estimated -$0.83 by +7.23%, while revenue for the quarter reached $360.00K , beating expectations by +111.76%.
Earnings released on 4 Nov 2020
EPS came in at -$0.77 falling short of the estimated -$0.68 by -13.24%, while revenue for the quarter reached $157.00K , beating expectations by +18.46%.
PRTA Stock Performance
Access detailed PRTA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.